SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Related Videos
Related Content

5 Different Infectious Diseases That Made Headlines This Week

March 25th 2023

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022

Which States Saw Greatest COVID-19 Mortality?

March 24th 2023

Vaccine Inequity With Dr. Leonard Friedland

January 28th 2022

Who is Most Vulnerable for Long COVID and Can These Factors be Mitigated?

March 23rd 2023

Can We Stave Off Vector-Borne Diseases From Encroaching Into New Areas?

March 22nd 2023

5 Different Infectious Diseases That Made Headlines This Week

March 25th 2023

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022

Which States Saw Greatest COVID-19 Mortality?

March 24th 2023

Vaccine Inequity With Dr. Leonard Friedland

January 28th 2022

Who is Most Vulnerable for Long COVID and Can These Factors be Mitigated?

March 23rd 2023

Can We Stave Off Vector-Borne Diseases From Encroaching Into New Areas?

March 22nd 2023

5 Different Infectious Diseases That Made Headlines This Week

March 25th 2023

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022

Which States Saw Greatest COVID-19 Mortality?

March 24th 2023

Vaccine Inequity With Dr. Leonard Friedland

January 28th 2022

Who is Most Vulnerable for Long COVID and Can These Factors be Mitigated?

March 23rd 2023

Can We Stave Off Vector-Borne Diseases From Encroaching Into New Areas?

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.